Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBT (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed EBT for 16 consecutive years, with $28.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 116.14% year-over-year to $28.3 million, compared with a TTM value of $254.9 million through Dec 2025, up 139.29%, and an annual FY2025 reading of $51.5 million, up 108.41% over the prior year.
  • EBT was $28.3 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $36.1 million in the prior quarter.
  • Across five years, EBT topped out at $369.6 million in Q1 2025 and bottomed at -$179.1 million in Q2 2025.
  • Average EBT over 5 years is -$51.6 million, with a median of -$67.7 million recorded in 2021.
  • The sharpest move saw EBT tumbled 366.37% in 2024, then surged 391.05% in 2025.
  • Year by year, EBT stood at -$62.9 million in 2021, then skyrocketed by 33.53% to -$41.8 million in 2022, then tumbled by 231.84% to -$138.7 million in 2023, then fell by 26.26% to -$175.1 million in 2024, then soared by 116.14% to $28.3 million in 2025.
  • Business Quant data shows EBT for ARWR at $28.3 million in Q4 2025, $36.1 million in Q3 2025, and -$179.1 million in Q2 2025.